Clinical trials: Induction Phase
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning
Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely…
- Trial name
- STARSCAPE-1 (NCT07184931)
- Testing
- Duvakitug
- Where
- 461 sites in United States, Argentina and 34 more
- Volunteers
- 980 people
- Sponsor
- Sanofi
Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).
- Trial name
- NCT02039505
- Testing
- Vedolizumab
- Where
- 59 sites in Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Toxic Epidermal Necrolysis
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).
- Trial name
- TEN (NCT02319616)
- Testing
- Clobetasol 0.05% ointment
- Where
- United States
- Sponsor
- University of California, Davis
Nasopharyngeal Neoplasms
Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of nasopharyngeal cancer.
- Trial name
- NCT00078494
- Testing
- EBV-LMP-2
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Anemia, Neoplasms
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Anemia is a frequent complication among cancer patients, both as a result of the malignancy of the disease and the aggressiveness of the treatment.
- Conditions
- Anemia, Neoplasms, Chemotherapeutic-Induced Anemia
- Trial name
- NCT05704894
- Testing
- Erythropoietin
- Volunteers
- 320 people
- Sponsor
- Blau Farmaceutica S.A.
AML, RUNX1-RUNX1T1 Fusion Protein Expression
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Leukemia is one of the common malignant tumors that threaten human health. Although the efficacy of AML treatment has improved significantly in recent years, it remains one of the major diseases threatening human health.
- Trial name
- NCT06744504
- Testing
- cytarabine, daunorubicin, idarubicin
- Where
- China
- Volunteers
- 284 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells and slow the growth of non-Hodgkin's lymphoma.
- Trial name
- NCT00003639
- Testing
- recombinant interferon alfa, chlorambucil, dexamethasone
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Scotland and Newcastle Lymphoma Group
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and peripheral blood stem cell transplant followed by donor lymphocyte infusion in treating older patients with chronic myeloid leukemia.
- Conditions
- Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease
- Trial name
- NCT00003145
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Heparin-induced Thrombocytopenia
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
- Trial name
- HITSOVA (NCT03809481)
- Testing
- Danaparoid Sodium, Argatroban
- Where
- 35 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 7 people
- Sponsor
- Aspen Global Incorporated
AML
Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML
Background The effects of granulocyte colony-stimulating factors (G-CSF) on recovery following induction chemotherapy are widely accepted. However, their impact on response and survival has not been clarified yet.
- Trial name
- TLG-AML-95-002 (NCT00820976)
- Testing
- G-CSF
- Volunteers
- 260 people
- Sponsor
- Turkish Leukemia Study Group
Infant, Premature, Diseases, Respiratory Insufficiency Syndrome of Newborn
Impact of CPAP Level on V/Q Mismatch in Premature Infants
Continuous positive airway pressure (CPAP) is used in premature infants to maintain lungs open and facilitate gas exchange. When ventilation/perfusion (V/Q) mismatch is present, areas of the lung that are open for gas exchange do…
- Trial name
- NCT02983825
- Testing
- Continuous positive airway pressure (CPAP); level changes
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital of Philadelphia
Bronchopulmonary Dysplasia
Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants.
- Trial name
- NCT01897987
- Testing
- Pneumostem®, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Medipost Co Ltd.
Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
- Trial name
- PALL (NCT02808442)
- Testing
- UCART19
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 13 people
- Sponsor
- Institut de Recherches Internationales Servier
Ureaplasma Infections
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
The purpose of this study is to determine whether intravenous azithromycin is effective in eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks gestation.
- Trial name
- AZIPIII (NCT01778634)
- Testing
- Azithromycin
- Where
- 7 sites in United States
- Volunteers
- 121 people
- Sponsor
- University of Maryland, Baltimore
Depression, Neurotoxicity
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease…
- Conditions
- Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00069927
- Testing
- Adderall-XR®, Concerta®
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with intrathecal liposomal cytarabine and prednisolone during maintenance therapy will decrease the CNS relapse rate in high-risk ALL patients.
- Trial name
- NCT00991744
- Testing
- Liposomal cytarabine, Intrathecal triple
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 100 people
- Sponsor
- Nordic Society for Pediatric Hematology and Oncology